Fendler WP, et al. - Researchers performed this prospective single-arm trial of 635 men, to assess the accuracy of ⁶⁸gallium-labeled ligands of the prostate-specific membrane antigen (PSMA)-11 positron emission tomographic (PET) imaging for localization of recurrent prostate cancer. Patients with biochemically recurrent prostate cancer and median prostate-specific antigen of 2.1 ng/mL displayed 84% to 92% positive predictive value of ⁶⁸Ga-PSMA-11 PET at 75% overall detection rate. The 3 readers of the PET images showed substantial agreement. The findings revealed that ⁶⁸Ga-PSMA-11 PET is valuable for detecting metastases earlier and may provide highly relevant information in a biochemical recurrence setting.